Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 3/20 | 0.65 |
| ▸ | ADK | P55263 | 14/20 | 0.56 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.47 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.47 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.47 |
| ▸ | MTOR | P42345 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19271869 | 1.00 | ADORA2A (0.65) | ADORA2AADKHASPINADORA3ADORA2B | |
| SCHEMBL6723537 | 1.00 | ADORA2A (0.65) | ADORA2AADKHASPINADORA3ADORA2B | |
| SCHEMBL1573050 | 1.00 | ADORA2A (0.65) | ADORA2AADKHASPINADORA3ADORA2B | |
| SCHEMBL13021352 | 1.00 | ADORA2A (0.65) | ADORA2AADKHASPINADORA3ADORA2B | |
| SCHEMBL2786078 | 1.00 | ADORA2A (0.65) | ADORA2AADKHASPINADORA3ADORA2B | |
| SCHEMBL12716058 | 1.00 | ADORA2A (0.65) | ADORA2AADKHASPINADORA3ADORA2B | |
| SCHEMBL13650003 | 1.00 | ADORA2A (0.65) | ADORA2AADKHASPINADORA3ADORA2B | |
| SCHEMBL15241432 | 1.00 | ADORA2A (0.65) | ADORA2AADKHASPINADORA3ADORA2B | |
| SCHEMBL13091999 | 1.00 | ADORA2A (0.65) | ADORA2AADKHASPINADORA3ADORA2B | |
| SCHEMBL6723371 | 0.91 | ADK (0.65) | ADORA2AADKHASPINADORA3MTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090253648-A1 | Tricyclic-Nucleoside Compounds for Treating Viral Infections | SMITHKLINE BEECHAM CORPORATION (US) | 2009-10-08 | — | — | US | disclosed |
| US-20090253648-A1 | Tricyclic-Nucleoside Compounds for Treating Viral Infections | SMITHKLINE BEECHAM CORPORATION (US) | 2009-10-08 | — | — | US | disclosed |
| US-20090208457-A1 | Tricyclic-Nucleoside Prodrugs for Treating Viral Infections | SMITHKLINE BEECHAM CORPORATION (US) | 2009-08-20 | — | — | US | disclosed |
| US-7534771-B2 | Tricyclic-nucleoside prodrugs for treating viral infections | SMITHKLINE BEECHAM CORPORATION (US) | 2009-05-19 | — | — | US | disclosed |
| US-7534771-B2 | Tricyclic-nucleoside prodrugs for treating viral infections | SMITHKLINE BEECHAM CORPORATION (US) | 2009-05-19 | — | — | US | disclosed |
| US-7524825-B2 | Tricyclic-nucleoside compounds for treating viral infections | SMITHKLINE BEECHAM CORPORATION (US) | 2009-04-28 | — | — | US | disclosed |
| US-7524825-B2 | Tricyclic-nucleoside compounds for treating viral infections | SMITHKLINE BEECHAM CORPORATION (US) | 2009-04-28 | — | — | US | disclosed |
| US-20090048189-A1 | TRICYCLIC-NUCLEOSIDE COMPOUNDS FOR TREATING VIRAL INFECTIONS | GENELABS TECHNOLOGIES, INC. | 2009-02-19 | — | — | US | disclosed |
| US-20090048189-A1 | TRICYCLIC-NUCLEOSIDE COMPOUNDS FOR TREATING VIRAL INFECTIONS | GENELABS TECHNOLOGIES, INC. | 2009-02-19 | — | — | US | disclosed |
| US-20070167383-A1 | NUCLEOSIDE COMPOUNDS FOR TREATING VIRAL INFECTIONS | GENELABS TECHNOLOGIES, INC. | 2007-07-19 | — | — | US | disclosed |
| US-20070167383-A1 | NUCLEOSIDE COMPOUNDS FOR TREATING VIRAL INFECTIONS | GENELABS TECHNOLOGIES, INC. | 2007-07-19 | — | — | US | disclosed |
| US-7244713-B2 | Nucleoside compounds for treating viral infections | GENELABS TECHNOLOGIES, INC. (US) | 2007-07-17 | — | — | US | disclosed |
| US-7244713-B2 | Nucleoside compounds for treating viral infections | GENELABS TECHNOLOGIES, INC. (US) | 2007-07-17 | — | — | US | disclosed |
| US-7202223-B2 | Nucleoside compounds for treating viral infections | GENELABS TECHNOLOGIES, INC. (US) | 2007-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048189-A1 | TRICYCLIC-NUCLEOSIDE COMPOUNDS FOR TREATING VIRAL INFECTIONS | TYMP, PNP, NSUN2 | ADORA2A 334/4885ADK 944/4885HASPIN 3224/4885 |
| US-20090208457-A1 | Tricyclic-Nucleoside Prodrugs for Treating Viral Infections | PNP, TYMP, HAVCR2 | ADORA2A 172/4885ADK 573/4885HASPIN 3203/4885 |
| US-20070167383-A1 | NUCLEOSIDE COMPOUNDS FOR TREATING VIRAL INFECTIONS | PNP, HAVCR2, SAMHD1 | ADORA2A 235/4885ADK 190/4885HASPIN 2576/4885 |
| US-20090253648-A1 | Tricyclic-Nucleoside Compounds for Treating Viral Infections | PNP, TYMP, NSUN2 | ADORA2A 145/4885ADK 365/4885HASPIN 3499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.